We found that the leptin–adiponectin ratio was associated with a greater number of metabolic abnormalities in patients with schizophrenia compared to leptin or adiponectin alone, suggesting from the data in [18] that this ratio is the preferential biomarker of MetS in patients with schizophrenia. The gene discussed is ADIPOQ; the disease is metabolic syndrome.